Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $1.67 billion. The enterprise value is $2.46 billion.
Important Dates
The last earnings date was Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RARE has 101.62 million shares outstanding. The number of shares has increased by 3.70% in one year.
| Current Share Class | 101.62M |
| Shares Outstanding | 101.62M |
| Shares Change (YoY) | +3.70% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 3.49% |
| Owned by Institutions (%) | 94.78% |
| Float | 83.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 22.47 |
| PS Ratio | 2.29 |
| Forward PS | 1.75 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.40
| Current Ratio | 1.40 |
| Quick Ratio | 1.12 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.27 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -44.08% |
| Return on Invested Capital (ROIC) | -32.20% |
| Return on Capital Employed (ROCE) | -54.76% |
| Weighted Average Cost of Capital (WACC) | 5.93% |
| Revenue Per Employee | $532,458 |
| Profits Per Employee | -$382,203 |
| Employee Count | 1,371 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 14.53 |
Taxes
| Income Tax | -6.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.27% in the last 52 weeks. The beta is 0.36, so RARE's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | -48.27% |
| 50-Day Moving Average | 15.51 |
| 200-Day Moving Average | 22.34 |
| Relative Strength Index (RSI) | 50.64 |
| Average Volume (20 Days) | 3,958,708 |
Short Selling Information
The latest short interest is 23.62 million, so 23.25% of the outstanding shares have been sold short.
| Short Interest | 23.62M |
| Short Previous Month | 20.15M |
| Short % of Shares Out | 23.25% |
| Short % of Float | 28.38% |
| Short Ratio (days to cover) | 6.81 |
Income Statement
In the last 12 months, RARE had revenue of $730.00 million and -$524.00 million in losses. Loss per share was -$5.18.
| Revenue | 730.00M |
| Gross Profit | -78.00M |
| Operating Income | -437.00M |
| Pretax Income | -530.00M |
| Net Income | -524.00M |
| EBITDA | -403.00M |
| EBIT | -437.00M |
| Loss Per Share | -$5.18 |
Full Income Statement Balance Sheet
The company has $401.00 million in cash and investments and $1.19 billion in debt, with a net cash position of -$785.00 million or -$7.72 per share.
| Cash & Investments | 401.00M |
| Total Debt | 1.19B |
| Net Cash | -785.00M |
| Net Cash Per Share | -$7.72 |
| Equity (Book Value) | -369.00M |
| Book Value Per Share | -3.70 |
| Working Capital | 155.00M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$437.00 million and capital expenditures -$5.00 million, giving a free cash flow of -$442.00 million.
| Operating Cash Flow | -437.00M |
| Capital Expenditures | -5.00M |
| Depreciation & Amortization | 34.00M |
| Net Borrowing | n/a |
| Free Cash Flow | -442.00M |
| FCF Per Share | -$4.35 |
Full Cash Flow Statement Margins
Gross margin is -10.68%, with operating and profit margins of -59.86% and -71.78%.
| Gross Margin | -10.68% |
| Operating Margin | -59.86% |
| Pretax Margin | -72.60% |
| Profit Margin | -71.78% |
| EBITDA Margin | -55.21% |
| EBIT Margin | -59.86% |
| FCF Margin | n/a |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.70% |
| Shareholder Yield | n/a |
| Earnings Yield | -31.43% |
| FCF Yield | -26.39% |
Analyst Forecast
The average price target for RARE is $24.80, which is 50.49% higher than the current price. The consensus rating is "Buy".
| Price Target | $24.80 |
| Price Target Difference | 50.49% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | 16.30% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -5.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.28 |
| Piotroski F-Score | 3 |